Since subsequent treatment after the failure of third-generation EGFR-TKIs is not well established, sequential afatinib and osimertinib showed promise in Asian NSCLC patients with EGFR mutations and T790M-mediated resistance, especially in those with Del19-positive disease [15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.